Fluid biomarkers in cerebral amyloid angiopathy.

Autor:	Savar SM; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; School of Psychology, Murdoch University, Murdoch, WA, Australia., Ma B; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; School of Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, WA, Australia., Hone E; School of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia., Jahan F; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; College of Science, Technology, Engineering and Mathematics, Murdoch University, Perth, WA, Australia., Markovic S; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; School of Psychology, Murdoch University, Murdoch, WA, Australia., Pedrini S; School of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.; Australian Alzheimer's Research Foundation, Nedlands, WA, Australia., Shemehsavar S; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; College of Science, Technology, Engineering and Mathematics, Murdoch University, Perth, WA, Australia., Easwaran V; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; School of Psychology, Murdoch University, Murdoch, WA, Australia., Taddei K; School of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.; Australian Alzheimer's Research Foundation, Nedlands, WA, Australia., Gardener S; School of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.; Australian Alzheimer's Research Foundation, Nedlands, WA, Australia., Chhatwal JP; Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., van Etten ES; Department of Neurology, Leiden University Medical Center, Leiden, Netherlands., van Osch MJP; Department of Radiology, Leiden University Medical Center, Leiden, Netherlands., Clarke D; Australian Alzheimer's Research Foundation, Nedlands, WA, Australia.; Sir Charles Gairdner Hospital, Perth Neurology Center, Nedlands, WA, Australia., Gnjec A; Australian Alzheimer's Research Foundation, Nedlands, WA, Australia.; Sir Charles Gairdner Hospital, Perth Neurology Center, Nedlands, WA, Australia., van Buchem MA; Department of Radiology, Leiden University Medical Center, Leiden, Netherlands., Wermer MJH; Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.; Department of Neurology, University Medical Center Groningen, Groningen, Netherlands., Hankey GJ; Medical School, The University of Western Australia, Crawley, WA, Australia.; Perron Institute for Neurological and Translational Science, Nedlands, WA, Australia., Greenberg SM; Haemorrhagic Stroke Research Program, Massachusetts General Hospital Stroke Research Center, Boston, MA, United States., Martins RN; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; School of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.; Australian Alzheimer's Research Foundation, Nedlands, WA, Australia.; Macquarie Medical School, Macquarie University, North Ryde, NSW, Australia., Sohrabi HR; Centre for Healthy Ageing, Health Future Institute, Murdoch University, Perth, WA, Australia.; School of Psychology, Murdoch University, Murdoch, WA, Australia.; School of Medical and Health Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australia.; Australian Alzheimer's Research Foundation, Nedlands, WA, Australia.; Macquarie Medical School, Macquarie University, North Ryde, NSW, Australia.
Jazyk:	angličtina
Zdroj:	Frontiers in neuroscience [Front Neurosci] 2024 Jan 26; Vol. 18, pp. 1347320. Date of Electronic Publication: 2024 Jan 26 (Print Publication: 2024).
DOI:	10.3389/fnins.2024.1347320
Abstrakt:	Cerebral amyloid angiopathy (CAA) is a type of cerebrovascular disorder characterised by the accumulation of amyloid within the leptomeninges and small/medium-sized cerebral blood vessels. Typically, cerebral haemorrhages are one of the first clinical manifestations of CAA, posing a considerable challenge to the timely diagnosis of CAA as the bleedings only occur during the later disease stages. Fluid biomarkers may change prior to imaging biomarkers, and therefore, they could be the future of CAA diagnosis. Additionally, they can be used as primary outcome markers in prospective clinical trials. Among fluid biomarkers, blood-based biomarkers offer a distinct advantage over cerebrospinal fluid biomarkers as they do not require a procedure as invasive as a lumbar puncture. This article aimed to provide an overview of the present clinical data concerning fluid biomarkers associated with CAA and point out the direction of future studies. Among all the biomarkers discussed, amyloid β, neurofilament light chain, matrix metalloproteinases, complement 3, uric acid, and lactadherin demonstrated the most promising evidence. However, the field of fluid biomarkers for CAA is an under-researched area, and in most cases, there are only one or two studies on each of the biomarkers mentioned in this review. Additionally, a small sample size is a common limitation of the discussed studies. Hence, it is hard to reach a solid conclusion on the clinical significance of each biomarker at different stages of the disease or in various subpopulations of CAA. In order to overcome this issue, larger longitudinal and multicentered studies are needed. Competing Interests: The authors declare that while some of their CAA research projects have been supported by commercial funding from Biogen Inc. and Alnylam Pharmaceuticals, this specific manuscript did not receive any funding and the funders of our research were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Savar, Ma, Hone, Jahan, Markovic, Pedrini, Shemehsavar, Easwaran, Taddei, Gardener, Chhatwal, van Etten, van Osch, Clarke, Gnjec, van Buchem, Wermer, Hankey, Greenberg, Martins and Sohrabi.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu